Three years of pharmaceutical reform, five major changes, affecting all pharmaceutical companies
Source:赛柏蓝
|
Author:赛柏蓝
|
Published time: 2018-08-20
|
1201 Views
|
Share:
This article is to commemorate the 3rd anniversary of the publication of article 44. For a long time, China's new drug research and development ability is low and accessibility is poor (Figure 1). Generic drugs cannot replace the original research due to their low level. The film "I Am not The God of Medicine" highlights this contradiction. For this reason, in the past three years, China's pharmaceutical industry has launched an unprecedented reform, attracting the attention of peers around the world. This reform, which started with Document No. 44 and culminated in two documents in 2017, has exerted a profound influence on the pharmaceutical industry, aiming at reaching international standards. According to the statistics of McKinsey expert Wang Jin, since the State Council issued the Opinions on Reforming the Evaluation and Approval System of Drugs and Medical Devices (Hereinafter referred to as "Document 44"), a total of 250 documents, regulations and opinions related to the reform have been issued between 2015 and May 2018, with a new policy issued every four days on average.
